CVS Health stock rises after medicare PBM limits stripped from tax bill

Published 16/06/2025, 21:00
© Reuters.

Investing.com -- CVS Health (NYSE:CVS) stock rose 1% on Wednesday after Bloomberg reported that Medicare Pharmacy Benefit Manager (PBM) limits were stripped from the Senate version of the tax bill.

The removal of these limits represents a positive development for CVS Health, which operates one of the largest PBM businesses in the United States through its Caremark division. PBMs act as intermediaries between drug manufacturers, health insurance companies, and pharmacies.

Other healthcare companies also saw gains following the news. UnitedHealth Group (NYSE:UNH) and Cigna (NYSE:CI) shares moved higher as these companies also have significant PBM operations that would have been affected by potential regulatory limits.

According to the report, the bill will also omit previously proposed cuts to Medicare Advantage programs. This omission is particularly beneficial for health insurers with large Medicare Advantage businesses, including Humana (NYSE:HUM).

Medicare Advantage plans, which are privately administered alternatives to traditional Medicare, have been a growing and profitable segment for health insurance companies in recent years.

The healthcare sector has faced regulatory uncertainty regarding potential reforms to drug pricing and healthcare administration. The removal of these provisions from the tax bill reduces some near-term regulatory pressure on companies operating in the PBM and Medicare Advantage spaces.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.